drugset
drugset / Trial / NCT06617000

A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

NCT06617000 ↗

Phase 1 Recruiting 38 enrolled SCG Cell Therapy Pte. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.

Timeline

Start
2022-10-25
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SCG101 Cell therapy — —

Indications

hepatocellular carcinoma